What one share of Zymeworks holds
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease.
Zymeworks’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-09-30; the balance sheet is as of 2026-09-30.
| Sales | $3.43 |
|---|---|
| Profit | $0.56 |
| Capex (buildings, equipment and software) | $0.01 |
| Free cash flow | −$1.46 |
| Cash and investments | $1.41 |
| Debt | $4.76 |
| Book value | $3.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.77 | −$3.58 | $0.09 | −$3.09 | — | $8.14 |
| 2021 | $0.51 | −$4.61 | $0.24 | −$3.93 | — | $5.34 |
| 2022 | $6.32 | $1.90 | $0.12 | $2.08 | — | $7.82 |
| 2023 | $1.10 | −$1.72 | $0.04 | −$1.75 | — | $6.63 |
| 2024 | $1.01 | −$1.62 | $0.03 | −$1.48 | — | $4.91 |
| 2025 | $1.41 | −$1.08 | $0.02 | −$0.46 | — | $3.60 |
Common questions about Zymeworks
How much does one share of Zymeworks earn?
Over the last 12 months, each share of Zymeworks earned $0.56 of profit on $3.43 of sales, keeping about 16¢ of every $1 (profit margin).
Does Zymeworks pay a dividend?
Zymeworks didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zymeworks’s book value per share?
Zymeworks’s book value is $3.63 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of September 30, 2026.
How much cash and debt does each share of Zymeworks have?
Each share of Zymeworks has $1.41 of cash and investments and $4.76 of debt, as of September 30, 2026.
What is Zymeworks’s free cash flow per share?
−$1.46 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings, equipment and software.
Has Zymeworks bought back shares?
Zymeworks’s share count rose about 50% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.